Recent research in selective cyclin-dependent kinase 4 inhibitors for anti-cancer treatment.
It is well known that cyclins and cyclin-dependent kinases (CDKs) play essential roles in regulation of the cell cycle. In past two decades, the scientific researches suggest that the cyclin D1/ CDK4 complex is a key regulator of the transition through the G1 phase of the cell cycle. Moreover, deregulation of the cyclin D /CDK4 pathway has been identified in multiple tumor types. Thus, CDK4 is a genetically validated therapeutic target; hence, there has been a surge of interests in finding selective CDK4 inhibitors as anti-cancer agents. This review will give the recent progress in the studies of structure, functions of CDK4 and highly selective and potent CDK4 inhibitors.
Liu
Ning
N
Department of Medicinal, Chemistry, School of Pharmaceutical Sciences, Shandong University, 44, West Culture Road, 250012 Ji'nan, Shandong, P.R. China.
Fang
Hao
H
Li
Yanling
Y
Xu
Wenfang
W
D000970:Antineoplastic Agents / Q000737:chemistry* / Q000494:pharmacology; D002227:Carbazoles / Q000737:chemistry / Q000494:pharmacology; D051358:Cyclin-Dependent Kinase 4 / Q000037:antagonists & inhibitors* / Q000737:chemistry / Q000378:metabolism; D016193:G1 Phase; D006801:Humans; D007211:Indoles / Q000737:chemistry / Q000494:pharmacology; D009369:Neoplasms / Q000188:drug therapy; D011743:Pyrimidines / Q000737:chemistry / Q000494:pharmacology; D011809:Quinones / Q000737:chemistry / Q000494:pharmacology; D000644:Quaternary Ammonium Compounds; D002243:Carbolines; D007212:Indolizines
D000970:Antineoplastic Agents; D002227:Carbazoles; D051358:Cyclin-Dependent Kinase 4; D007211:Indoles; D011743:Pyrimidines; D011809:Quinones; C069346:fascaplysine; D000644:Quaternary Ammonium Compounds; D002243:Carbolines; D007212:Indolizines